Profile

Aulis Capital is a venture capital firm with a focus on life sciences and healthcare, based across Hong Kong, Beijing, Shanghai, Silicon Valley, and Boston. The firm was founded in October 2025 by Nisa Leung, a former managing partner at Qiming Venture Partners, and is led by a team of experienced operators, investors, and advisors. Aulis Capital distinguishes itself by leveraging its extensive global network and expertise in the medical technology field to support transformative healthcare innovations.

The firm invests in early- and growth-stage companies that are developing innovative drugs, digital healthcare solutions, and AI-driven healthcare technologies. Aulis Capital typically invests in the $10-50 million range for Series A through late-stage companies. The firm recently closed its first fund, Aulis Capital Fund I, with $200 million in commitments. It focuses geographically on nurturing startups in key regions around the globe.

Notable investments by Aulis Capital include EpiBiologics, a US-based company that raised $107 million in a Series B round to advance its protein degradation pipeline. The firm is committed to fostering companies that redefine potential in the medical sector.

Industry

HealthTech Life Sciences AI Medical Devices Healthcare Services Digital Biotechnology

Aulis Capital Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
Aulis Capital Fund I, L.P.
Venture Capital (VC)
Digital
Healthcare Services
AI
Life Sciences
Seed
Late Stage (Series C+)
North America
Asia
$10-50 m
$200 M
November 2026

Contacts

Name
Title
Email
avatar
Brian Zhu Vice President
Vice President
b•••@•••
avatar
Nisa Leung Managing Partner
Managing Partner
n•••@•••
Upgrade to see contacts
avatar
bX8BHSqyfkGsK0Ux bX8BHSqyfkGsK0Ux
bX8BHSqyfkGsK0Ux
avatar
bX8BHSqyfkGsK0Ux bX8BHSqyfkGsK0Ux
bX8BHSqyfkGsK0Ux
avatar
bX8BHSqyfkGsK0Ux bX8BHSqyfkGsK0Ux
bX8BHSqyfkGsK0Ux
Investment-team contacts for Aulis Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Aulis Capital

Aulis Capital is a venture capital firm. It backs companies at Seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.
Aulis Capital is located in Kowloon Bay, Hong Kong, Hong Kong.
Aulis Capital was founded in 2025.
Aulis Capital invests in companies and startups in HealthTech, Life Sciences, AI, Medical Devices, Healthcare Services, Digital, Biotechnology.
Aulis Capital invests in companies and startups in North America, Asia.
Aulis Capital invests in companies and startups at Seed, Series A, Series B, Late Stage (Series C+).
Aulis Capital usually invests $10-50 m on average.
Aulis Capital last fund was created/launched in 2026-11-11
Aulis Capital can be reached through its website auliscapital.com and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Aulis Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Aulis Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 19 November, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.